QC
DXCM icon

Quantessence Capital’s DexCom DXCM Stock Holding History

Quantessence Capital’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,132
Closed -$555K – 367
2024
Q4 		$555K Buy
+7,132
New +$528K 0.23% 109

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Quantessence Capital's DXCM Position: Q1 2025 in Review

Quantessence Capital sold out of DexCom (DXCM) in Q1 2025, closing a stake of 7,132 shares — an estimated $555K sold.

Quantessence Capital first reported a position in DXCM in Q4 2024 and held it in 1 quarter. The position peaked at $555K in Q4 2024. 932 funds tracked by Wall St. Rank hold DXCM as of Q1 2025.

  • Quantessence Capital reported no remaining DexCom position as of Q1 2025 after selling out during the quarter.
  • Quantessence Capital sold 7,132 DexCom shares in Q1 2025, an estimated $555K.
  • Quantessence Capital first reported a position in DexCom in Q4 2024 and held it in 1 quarter.
  • Quantessence Capital's DexCom position peaked at $555K in Q4 2024.
  • 932 funds tracked by Wall St. Rank held DexCom as of Q1 2025.

Based on Quantessence Capital's 13F filing for Q1 2025, filed 15 May 2025.